Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device

Journal of Controlled Release

Volumn 117, Issue 1, 2007, Pages 80-89

  Gu, Frank ^a   Neufeld, Ronald ^a   Amsden, Brian ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Biodegradable elastomer; Photo polymerization; Protein stability and bioactivity; Sustainable protein release

Indexed keywords

BIODEGRADATION; COMPUTATIONAL GEOMETRY; CROSSLINKING; ELASTOMERS; MOLECULAR WEIGHT; PHOTOPOLYMERIZATION;

ACRYLATED MACROMERS; BIODEGRADABLE ELASTOMERS; PROTEIN STABILITY AND BIOACTIVITY; SUSTAINABLE PROTEIN RELEASE;

PROTEINS;

ACRYLIC ACID DERIVATIVE; ELASTOMER; EXCIPIENT; GAMMA INTERFERON; INTERLEUKIN 2; POLYCAPROLACTONE; PROTEIN; VASCULOTROPIN;

ARTICLE; BIODEGRADABLE IMPLANT; BIODEGRADATION; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FREEZE DRYING; GEOMETRY; KINETICS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN SECRETION; SUSTAINED DRUG RELEASE;

CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; ELASTOMERS; FREEZE DRYING; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON TYPE II; INTERLEUKIN-2; LACTIC ACID; LINEAR MODELS; MOLECULAR WEIGHT; POLYGLYCOLIC ACID; POLYMERS; PROTEINS; TENSILE STRENGTH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846557412     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.09.077     Document Type: Article

References (51)

1. Reichert J.M., and Paquette C. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. Curr. Opin. Mol. Ther. 5 2 (2003) 139-147
2. Hermeling S., Crommelin D.J.A., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 6 (2004) 897-903
3. Lemaire V., Belair J., and Hildgen P. Structural modeling of drug release from biodegradable porous matrices based on a combined diffusion/erosion process. Int. J. Pharm. 258 1-2 (2003) 95-107
4. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., Yang C.W., and Park J.S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control. Release 84 3 (2002) 115-123
5. Sah H., Toddywala R., and Chien Y.W. Continuous release of proteins from biodegradable microcapsules and in-vivo evaluation of their potential as a vaccine adjuvant. J. Control. Release 35 2-3 (1995) 137-144
6. Hong K.D., Ahn Y.S., Go J.T., Kim M.S., Yuk S.H., Shin H.S., Rhee J.M., Khang G., and Lee H.B. Preparation of double layered nanosphere using dextran and poly(l-lactide-co-glycolide). Polymer-Korea 29 3 (2005) 260-265
7. Kim H.K., Chung H.J., and Park T.G. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. J. Control. Release 112 2 (2006) 167-174
8. Feng L., Qi M.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., and Nagai T. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 112 1 (2006) 35-42
9. Sinha V.R., and Trehan A. Biodegradable microspheres for protein delivery. J. Control. Release 90 (2003) 261-280
10. Sah H., and Bahl Y. Effects of aqueous phase composition upon protein destabilization at water/organic solvent interface. J. Control. Release 106 1-2 (2005) 51-61
11. Li L., and Schwendeman S.P. Mapping neutral microclimate pH in PLGA microspheres. J. Control. Release 101 (2005) 163-173
12. Ding A.G., and Schwendeman S.P. Determination of water-soluble acid distribution in poly(lactide-co-glycolide). J. Pharm. Sci. 93 2 (2004) 322-331
13. Ibrahim M.A., Ismail A., Fetouh M.I., and Gopferich A. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release 106 3 (2005) 241-252
14. van de Weert M., Hennink W.E., and Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17 10 (2000) 1159-1167
15. Amsden B., and Cheng Y.L. A generic protein delivery system based on osmotically rupturable monoliths. J. Control. Release 33 1 (1995) 99-105
16. Carelli V., Di Colo G., Guerrini C., and Nannipieri E. Drug release from silicone elastomer through controlled polymer cracking: an extension to macromolecular drugs. Int. J. Pharm. 50 3 (1989) 181-188
17. Di Colo G. Controlled drug release from implantable matrices based on hydrophobic polymers. Biomaterials 13 12 (1992) 850-856
18. Amsden B. A model for osmotic pressure driven release from cylindrical rubbery polymer matrices. J. Control. Release 93 (2003) 249-258
19. Amsden B. Osmotically activated protein release from electrostatically generated polymer microbeads. AIChE J. 42 (1996) 3253-3266
20. Wright J., Chandrasekaran S.K., Gale R., and Swanson D. Model for the release of osmotically active agents from monolithic polymeric matrices. AIChE Symp. Ser. 77 206 (1981)
21. Schirrer R., Thepin P., and Torres G. Water absorption, swelling, rupture and salt release in salt-silicone rubber compounds. J. Mater. Sci. 27 (1992) 3424-3434
22. Amsden B.G., Cheng Y.L., and Goosen M.F.A. A mechanistic study of the release of osmotic agents from polymeric monoliths. J. Control. Release 30 1 (1994) 45-56
23. Amsden B., Misra G., Gu F., and Younes H. Synthesis and characterization of a photocrosslinked biodegradable elastomer. Biomacromolecules 5 6 (2004) 2479-2486
24. Gu F., Younes H.M., El-Kadi A.O.S., Neufeld R.J., and Amsden B.G. Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer. J. Control. Release 102 3 (2005) 607-617
25. Gu F., Neufeld R.J., and Amsden B. Osmotic driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar and adjustable. Pharm. Res. 23 4 (2006) 782-789
26. Dee K., Puleo D.A., and Bizios R. An Introduction To Tissue-Biomaterial Interactions (2002), John Wiley and Sons
27. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 6 (2003) 669
28. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., and Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302 (1983) 305-310
29. Shenderova A., Burke T.G., and Schwendeman S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16 2 (1999) 241-248
30. Ilan N., Tucker A., and Madri J. Vascular endothelial growth factor expression, beta-catenin tyrosine phosphorylation, and endothelial proliferative behavior: a pathway for transformation?. Lab. Invest. 83 8 (2003) 1105-1115
31. Gillis S., Ferm M., Ou W., and Smith K. T-cell growth-factor - parameters of production and a quantitative microassay for activity. J. Immunol. 120 6 (1978) 2027-2032
32. Lu F., Plummer C.J.G., Cantwell W.J., and Kausch H.H. Toughening mechanisms in modified epoxy resins with different crosslink densities. Polym. Bull. 37 3 (1996) 399
33. Amsden B.G., and Cheng Y.L. Enhanced fraction releasable above percolation threshold from monoliths containing osmotic excipients. J. Control. Release 31 1 (1994) 21-32
34. Mulkerrin M., and Wetzel R. pH-dependence of the reversible and irreversible thermal-denaturation of gamma-interferons. Biochemistry-US 28 16 (1989) 6556-6561
35. Ricci M.S., Sarkar C.A., Fallon E.M., Lauffenburger D.A., and Brems D.N. pH dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor. Protein Sci. 12 5 (2003) 1030-1038
36. Goolcharran C., Cleland J.L., Keck R., Jones A.J.S., and Borchardt R.T. Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides. AAPS PharmSci 2 1 (2000)
37. Richardson T.P., Peters M.C., Ennett A.B., and Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19 11 (2001) 1029
38. Cleland J.L., Duenas E.T., Park A., Daugherty A., Kahn J., Kowalski J., and Cuthbertson A. Development of poly-(d,l-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control. Release 72 1-3 (2001) 13
39. Yang J., and Cleland J.L. Factors affecting the in vitro release of recombinant human interferon-γ from PLGA microspheres. J. Pharm. Sci. 86 8 (1997) 908-914
40. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154 (1997) 123-140
41. Thomas T., Kohane D., Wang A., and Langer R. Microparticulate formulations for the controlled release of interleukin-2. J. Pharm. Sci. 93 5 (2004) 1100-1109
42. T.I.C.G.D.c.S. Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New Engl. J. Med. 324 (1991) 509-516
43. Smith K. Interleukin-2- inception, impact, and implications. Science 240 (1988) 1169-1176
44. Eton O., Rosenblum M.G., Legha S.S., Zhang W.H., East M.J., Bedikian A., Papadopoulos N., Buzaid A., and Benjamin R.S. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95 1 (2002) 127
45. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., and Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17 7 (1999) 2105
46. Thompson J.A., Gold P.J., Markowitz D.R., Byrd D.R., Lindgren C.G., and Fefer A. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J. Sci. Am. 3 (1997) S29
47. Engelhardt M., Wirth K., Mertelsmann R., Lindemann A., and Brennscheidt U. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2. Eur. J. Cancer 33 7 (1997) 1050
48. Abrams J.S., Rayner A.A., Wiernik P.H., Parkinson D.R., Eisenberger M., Aronson F.R., Gucalp R., Atkins M.B., and Hawkins M.J. High-dose recombinant interleukin-2 alone- a regimen with limited activity in the treatment of advanced renal-cell carcinoma. J. Natl. Cancer Inst. 82 14 (1990) 1202
49. Krum J.M., Mani N., and Rosenstein J.M. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 110 4 (2002) 589
50. Egilmez N.K., Jong Y.S., Iwanuma Y., Jacob J.S., Santos C.A., Chen F.A., Mathiowitz E., and Bankert R.B. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft SCID mouse model. Cancer Immunol. Immunother. 46 1 (1998) 21
51. Airoldi I., Meazza R., Croce M., Di Carlo E., Piazza T., Cocco C., D'Antuono T., Pistoia V., Ferrini S., and Corrias M.V. Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity. Br. J. Cancer 90 11 (2004) 2210